



INDEPENDENT AUDITOR'S REVIEW REPORT


**Review Report to Board of Directors
Dr Lalchandani Labs Limited**

We have reviewed the accompanying Statement of standalone unaudited financial results of **Dr Lalchandani Labs Limited** ('the Company') for the half year ended on 30th September, 2018. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For AASM & Co.
Chartered Accountants
FRN-030481N


Ashish Arora
Partner
M.No- 516241



Place: New Delhi
Date : 14/11/2018



STANDALONE STATEMENT OF ASSETS AND LIABILITIES

Amount in Rs. (Lacs)

Sr. No.	Particulars	As at	As at
		30.09.2018	31.03.2018
		Un-audited	Audited
1	Shareholders' Funds		
	(a) Share Capital	433.31	293.31
	(b) Reserves and Surplus	339.50	39.98
	(c) Money received against share warrants		-
	Sub-total-Shareholders' Funds	772.81	333.29
2	Share application money pending allotment		
3	Non Current Liabilities		
	(a) Long Term Borrowings	56.02	182.37
	(b) Deferred Tax Liability	2.39	2.39
	(c) Other Long Term Liabilities	-	-
	(d) Long Term Provisions	-	-
	Sub-total-Non Current Liabilities	58.41	184.76
4	Current Liabilities		
	(a) Short Term Borrowings	5.05	5.06
	(b) Trade Payables	84.22	68.17
	(c) Other Current Liabilities	12.48	21.87
	(d) Short Term Provisions	13.88	7.03
	Sub-total-Current Liabilities	115.63	102.13
	TOTAL EQUITY AND LIABILITIES	946.85	620.18
II	ASSETS		
1	Non-Current Assets		
	(a) Fixed Assets		
	(i) Tangible assets	297.81	205.36
	(ii) Intangible assets	17.42	0.45
	(b) Non Current Investments	24.10	24.10
	(c) Long Term Loans & Advances	-	-
	(d) Other Non Current Assets	57.17	8.25
	Sub-total-Non Current Assets	396.50	238.16






STANDALONE STATEMENT OF ASSETS AND LIABILITIES

Amount in Rs. (Lacs)

Sr. No.	Particulars	As at 30.09.2018	As at 31.03.2018
		Un-audited	Audited
2	Current Assets		
	(a) Current Investments	-	-
	(b) Inventories	28.30	27.12
	(c) Trade Receivables	182.98	112.06
	(d) Cash & cash equivalents	130.77	90.86
	(e) Short Term Loans & Advances	105.77	107.89
	(f) Other Current Assets	102.53	44.09
	Sub-total-Current Assets	550.35	382.02
	TOTAL ASSETS	946.85	620.18

For Dr Lalchandani Labs Limited

(Mohit Lalchandani)
Whole Time Director
(DIN: 07873508)



New Delhi
14-Nov-18





STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2018

Amount Rs. (in Lacs)

Sr. No.	Particulars	Half Year Ended		For the Year Ended	Previous Year Ended
		30.09.2018	30.09.2017	31.03.2018	31.03.2017
		Un-audited	Audited	Audited	Audited
I	Revenue from Operations	261.70	264.86	494.45	452.02
II	Other Income	-	0.92	2.70	8.93
III	Total Revenue(I+II)	261.70	265.78	497.15	460.95
IV	Expenses				
	(a) Cost of materials consumed	62.74	60.13	110.17	206.14
	(b) Purchases of stock in trade	40.15	58.23	112.44	207.38
	(c) Changes in inventories of finished goods, work in progress and stock in trade	- 1.18	1.91	- 2.27	- 1.24
	(d) Employee benefits expense	41.79	28.87	70.78	35.97
	(e) Finance Cost	8.87	13.74	26.19	35.83
	(f) Depreciation and amortisation expense	15.22	-	13.08	16.93
	(g) Other Expenses	106.72	61.22	159.57	95.35
	Total Expenses	235.34	163.96	379.78	390.22
V	Profit before exceptional and extraordinary items and tax (III - IV)	26.36	101.82	117.36	70.73
VI	Exceptional Items			-	-
VII	Profit extraordinary items and tax (V - VI)	26.36	101.82	117.36	70.73
VIII	Extraordinary Items			-	-
IX	Profit before tax (VIII - VIII)	26.36	101.82	117.36	70.73
X	Tax Expenses :				
	(1) Current Tax	6.85	25.31	32.14	21.86
	(2) Deferred Tax	-	-	2.39	-
XI	Profit / (Loss) from Period from continuing operations (VII - VIII)	19.51	76.51	82.84	48.87
XII	Profit (Loss) from discontinuing Operations	-	-	-	-
XIII	Tax Expense of Discontinuing operations	-	-	-	-





Amount Rs. (in Lacs)

Sr. No.	Particulars	Half Year Ended		For the Year Ended	Previous Year Ended
		30.09.2018	30.09.2017	31.03.2018	31.03.2017
		Un-audited	Audited	Audited	Audited
XIV	Profit / (Loss) from Discontinuing optrtstions (After Tax XII- XIII)	-	-	-	-
XV	Profit (Loss) for the period (XI +XIV)	19.51	76.51	82.84	48.87
XVI	Earnings Per Share of Rs. 10 Each (Not Annualised)				
	(a) Basic (Rs.)	0.45	5.45	2.82	5.32
	(b) Diluted (Rs.)	0.45	5.45	2.82	5.32

Notes:

1. The financial results were reviewed by the audit committee and approved by the Board of directors at its meeting held on 14th November, 2018.
2. There were no investor complaints received / pending as at 30th September, 2018
3. The company does not have more than one reportable segment in terms of AS-17 issued by ICAI. Hence segment wise reporting is not applicable.

For Dr Lalchandani Labs Limited

(Mohit Lalchandani)
Whole Time Director
(DIN:07873508)

New Delhi

14-Nov-18

